Over 50,000 Tasmanians will have federally funded access to the first vaccine for a respiratory disease that can feel “worse ...

Striking new data from the Canadian Institute for Health Information (CIHI) shows hospitalization rates for ...

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head studyFirst head-to-head, double-blind, ...

Approximately 3 million adults aged 80 and over and care home residents are set to get the RSV vaccine on the NHS. Read more about the eligibility expansion.

New RSV tools can prevent infant hospitalizations, but access varies by province. Who is responsible for ensuring vaccine ...

Hospital admission rates for vaccine-preventable respiratory diseases more than doubled in 2024-2025 compared with ...

The Albanese Government is introducing free Respiratory Syncytial Virus (RSV) vaccinations for older Australians to ensure they are protected from the ...

Immunocompetent adults younger than 50 years of age experience a substantial HZ burden, with incidence rates comparable to older age groups.

Cases of the virus are abnormally high this year, according to health experts, and are especially dangerous for children.

UCSF study shows that aging connective tissue in the lungs brings on a catastrophic immune response in older people.